Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Closed
26 Feb, 20:00
NYSE NYSE
$
27. 10
+0.01
+0.04%
Pre Market
$
27. 06
-0.04 -0.15%
151.52B Market Cap
14.55 P/E Ratio
1.63% Div Yield
24,554,948 Volume
1.43 Eps
$ 27.09
Previous Close
Day Range
26.87 27.27
Year Range
20.92 27.94
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PFE earnings report is expected in 59 days (27 Apr 2026)
Opinion: Pfizer (PFE) Stock Will Hit $22 Before It Hits $33 During Trump's Presidency

Opinion: Pfizer (PFE) Stock Will Hit $22 Before It Hits $33 During Trump's Presidency

Donald Trump's electoral victory has shaken the market, mostly in a good way.

247wallst | 1 year ago
Relative Strength Alert For Pfizer

Relative Strength Alert For Pfizer

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Pfizer presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Forbes | 1 year ago
Pfizer: Discounted For A Reason - But Dividend Story Remains Rich

Pfizer: Discounted For A Reason - But Dividend Story Remains Rich

PFE's core portfolio and strategic acquisitions continue to deliver decent results, no matter the lumpy sales contribution from Comirnaty and Paxlovid. The company raised their FY2024 core portfolio sales guidance, with the richer adj EPS numbers signaling the management's promising progress in cost and operational optimization. Even so, PFE continues to face massive patent cliff headwinds through 2030, with $31.58B of its annualized FQ3'24 revenues at stake.

Seekingalpha | 1 year ago
2 Healthcare Dividend Stocks That Are Screaming Buys in November

2 Healthcare Dividend Stocks That Are Screaming Buys in November

One stock yields 6% today. Another has grown its dividend by 460% over the past decade.

Fool | 1 year ago
3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now

3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now

Pfizer is trading above its 52-week low but is still a dirt cheap buy.

Fool | 1 year ago
PFE or NVO: Which Is the Better Value Stock Right Now?

PFE or NVO: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
1 Green Flag That's Also a Red Flag for Pfizer Stock

1 Green Flag That's Also a Red Flag for Pfizer Stock

An activist investor has correctly identified a dysfunctional area of the business.

Fool | 1 year ago
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?

Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?

Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.

Zacks | 1 year ago
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 year ago
Is Pfizer Stock a Bargain for Long-Term Investors?

Is Pfizer Stock a Bargain for Long-Term Investors?

Wall Street's bearish take on this proven innovator may not be warranted.

Fool | 1 year ago
This Beaten-Down Stock Just Gave Investors More Good News: Is it a Buy?

This Beaten-Down Stock Just Gave Investors More Good News: Is it a Buy?

Slowly but surely, the company's prospects are looking more attractive.

Fool | 1 year ago
3 Potential Catalysts That Could Lift Pfizer Stock Before 2025

3 Potential Catalysts That Could Lift Pfizer Stock Before 2025

The pipeline could yield a winner, but so could a few organizational changes.

Fool | 1 year ago
Loading...
Load More